Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The company is headquartered in Cambridge, Massachusetts and currently employs 261 full-time employees. The company went IPO on 2020-07-16. The Company’s initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. Its Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including RLY-2608. RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinositide 3 kinase alpha (PI3Kα) inhibitor in clinical development. The company is the lead program in its efforts to discover and develop mutant selective inhibitors of PI3Kα.
Follow-Up Questions
Who is the CEO of Relay Therapeutics Inc?
Dr. Sanjiv Patel is the President of Relay Therapeutics Inc, joining the firm since 2017.
What is the price performance of RLAY stock?
The current price of RLAY is $4.52, it has decreased 0.54% in the last trading day.
What are the primary business themes or industries for Relay Therapeutics Inc?
Relay Therapeutics Inc belongs to Biotechnology industry and the sector is Health Care
What is Relay Therapeutics Inc market cap?
Relay Therapeutics Inc's current market cap is $780.1M
Is Relay Therapeutics Inc a buy, sell, or hold?
According to wall street analysts, 11 analysts have made analyst ratings for Relay Therapeutics Inc, including 7 strong buy, 8 buy, 3 hold, 0 sell, and 7 strong sell
